Development of carmustine loaded PLGA-PEG conjugates for nose to brain targeting
By: Potdar, Mrugendra Bhojraj
.
Contributor(s): Jain, Neetesh Kumar.
Publisher: Bangalore Association of Pharmaceutical Teachers of India (APTI) 2022Edition: Vol.56(4), Oct-Dec.Description: 1076-1082p.Subject(s): PHARMACEUTICSOnline resources: Click here
In:
Indian journal of pharmaceutical education and researchSummary: Intranasal drug delivery is a promising route for drug delivery directly to the brain
for acute or chronic treatments. A direct route to the brain offers a rapid approach
to delivering drugs to the central nervous system without using the parenteral route.
Carmustine is a nitrosourea used to treat brain tumors, multiple myeloma, lymphoma,
and Hodgkin’s disease but its use is limited by a very little half-life in the body fluids. The
nanoparticles have shown great potential to overcome problems related to shorten shelf
life. The present study aims to develop a nose-to-brain delivery system for Carmustine
to prevent degradation and prolong it’s bioavailability at the target site. It has shown
that the nanoparticles have uniform size and shape and were found to be 231±21.2 nm
with 0.128 PDI. The system has stabilized with sufficient surface charge and the zeta
potential of the system was found to be -21.2±2.3 mV. After 24 h, cumulative drug
release from the prepared system was found to be the maximum release of around
96.69±3.38 in the phosphate buffer pH 6.8.
| Item type | Current location | Call number | Status | Date due | Barcode | Item holds |
|---|---|---|---|---|---|---|
Articles Abstract Database
|
School of Pharmacy Archieval Section | Not for loan | 2023-0104 |
Intranasal drug delivery is a promising route for drug delivery directly to the brain
for acute or chronic treatments. A direct route to the brain offers a rapid approach
to delivering drugs to the central nervous system without using the parenteral route.
Carmustine is a nitrosourea used to treat brain tumors, multiple myeloma, lymphoma,
and Hodgkin’s disease but its use is limited by a very little half-life in the body fluids. The
nanoparticles have shown great potential to overcome problems related to shorten shelf
life. The present study aims to develop a nose-to-brain delivery system for Carmustine
to prevent degradation and prolong it’s bioavailability at the target site. It has shown
that the nanoparticles have uniform size and shape and were found to be 231±21.2 nm
with 0.128 PDI. The system has stabilized with sufficient surface charge and the zeta
potential of the system was found to be -21.2±2.3 mV. After 24 h, cumulative drug
release from the prepared system was found to be the maximum release of around
96.69±3.38 in the phosphate buffer pH 6.8.
Click on an image to view it in the image viewer
There are no comments for this item.